scholarly journals Chylous Ascites: Evaluation and Management

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Said A. Al-Busafi ◽  
Peter Ghali ◽  
Marc Deschênes ◽  
Philip Wong
Keyword(s):  
Lymphatic System ◽  
Congenital Abnormalities ◽  
Traumatic Injury ◽  
Chylous Ascites ◽  
Peritoneovenous Shunt ◽  
Triglyceride Content ◽  
Intrahepatic Portosystemic Shunt ◽  
Abdominal Malignancy ◽  
Fat Diets ◽  
Strong Suspicion

Chylous ascites refers to the accumulation of lipid-rich lymph in the peritoneal cavity due to disruption of the lymphatic system secondary to traumatic injury or obstruction. Worldwide, abdominal malignancy, cirrhosis, and tuberculosis are the commonest causes of CA in adults, the latter being most prevalent in developing countries, whereas congenital abnormalities of the lymphatic system and trauma are commonest in children. The presence of a milky, creamy appearing ascitic fluid with triglyceride content above 200 mg/dL is diagnostic, and, in the majority of cases, unless there is a strong suspicion of malignancy, further investigations are not required in patients with cirrhosis. If an underlying cause is identified, targeted therapy is possible, but most cases will be treated conservatively, with dietary support including high-protein and low-fat diets supplemented with medium-chain triglycerides, therapeutic paracentesis, total parenteral nutrition, and somatostatins. Rarely, resistant cases have been treated by transjugular intrahepatic portosystemic shunt, surgical exploration, or peritoneovenous shunt.

Peritoneovenous Shunt for Chylous Ascites after Lung Transplantation for Lymphangioleiomyomatosis

2012 ◽  
Vol 44 (5) ◽  
pp. 1390-1393 ◽  
Author(s):  
T. Kanou ◽  
T. Nakagiri ◽  
M. Minami ◽  
M. Inoue ◽  
Y. Shintani ◽  
...  
Keyword(s):  
Lung Transplantation ◽  
Chylous Ascites ◽  
Peritoneovenous Shunt

Peritoneovenous Shunt After Failure of Octreotide Treatment for Chylous Ascites in Lymphangioleiomyomatosis

2007 ◽  
Vol 52 (11) ◽  
pp. 3188-3190 ◽  
Author(s):  
Laurent Lefrou ◽  
Louis d’Alteroche ◽  
Yahia Harchaoui ◽  
Dominique Franco ◽  
Etienne Henry Metman
Keyword(s):  
Chylous Ascites ◽  
Peritoneovenous Shunt ◽  
Octreotide Treatment

scholarly journals Specific Wheat Fractions Influence Hepatic Fat Metabolism in Diet-Induced Obese Mice

Nutrients ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 2348
Author(s):  
Graf ◽  
Weitkunat ◽  
Dötsch ◽  
Liebisch ◽  
Döring ◽  
...  
Keyword(s):  
Short Chain Fatty Acids ◽  
Whole Grain ◽  
Beneficial Effects ◽  
White Flour ◽  
Α Diversity ◽  
Affect Body Weight ◽  
Triglyceride Content ◽  
Hepatic Fat ◽  
Whole Grain Flour ◽  
Fat Diets

Low whole grain consumption is a risk factor for the development of non-communicable diseases such as type 2 diabetes. Dietary fiber and phytochemicals are bioactive grain compounds, which could be involved in mediating these beneficial effects. These compounds are not equally distributed in the wheat grain, but are enriched in the bran and aleurone fractions. As little is known on physiological effects of different wheat fractions, the aim of this study was to investigate this aspect in an obesity model. For twelve weeks, C57BL/6J mice were fed high-fat diets (HFD), supplemented with one of four wheat fractions: whole grain flour, refined white flour, bran, or aleurone. The different diets did not affect body weight, however bran and aleurone decreased liver triglyceride content, and increased hepatic n-3 polyunsaturated fatty acid (PUFA) concentrations. Furthermore, lipidomics analysis revealed increased PUFA concentration in the lipid classes of phosphatidylcholine (PC), PC-ether, and phosphatidylinositol in the plasma of mice fed whole grain, bran, and aleurone supplemented diets, compared to refined white flour. Furthermore, bran, aleurone, and whole grain supplemented diets increased microbial α-diversity, but only bran and aleurone increased the cecal concentrations of short-chain fatty acids. The effects on hepatic lipid metabolism might thus at least partially be mediated by microbiota-dependent mechanisms.

Extracorporeal Peritoneovenous Shunt for the Management of Postaneurysmectomy Chylous Ascites in a Marfan Patient

2010 ◽  
Vol 90 (1) ◽  
pp. 281-284 ◽  
Author(s):  
Gabriele Di Luozzo ◽  
Corey Scurlock ◽  
Jeffrey I. Mechanick ◽  
Randall B. Griepp
Keyword(s):  
Chylous Ascites ◽  
Peritoneovenous Shunt ◽  
Marfan Patient

Peritoneovenous shunt in the management of paediatric chylous ascites

1985 ◽  
Vol 72 (6) ◽  
pp. 443-444 ◽  
Author(s):  
R. S. C. Kerr ◽  
S. J. A. Powis ◽  
J. R. Y. Ross ◽  
C. J. E. Wynne-Williams
Keyword(s):  
Chylous Ascites ◽  
Peritoneovenous Shunt

Malignant Ascites

2020 ◽  
Vol 04 (03) ◽  
pp. 334-342
Author(s):  
Ahmed Elsakka ◽  
Hooman Yarmohammadi
Keyword(s):  
Diuretic Therapy ◽  
Malignant Ascites ◽  
Evidence Based ◽  
Indwelling Catheter ◽  
Management Guidelines ◽  
Peritoneovenous Shunt ◽  
Intrahepatic Portosystemic Shunt ◽  
Large Volume Paracentesis ◽  
High Level

AbstractMalignant ascites negatively impacts patient's quality of life and has significant impact on the health care resources. Majority of management guidelines are based on systemic reviews that have predominately relied on retrospective data. Therefore, there is lack of high-level evidence-based studies. In this review, the etiologies, pathophysiology, and various treatment methods including diuretic therapy, large volume paracentesis, indwelling catheter placement, peritoneovenous shunt, transjugular intrahepatic portosystemic shunt, and other available novel and/or experimental options are reviewed.

scholarly journals Surgical Management of Lymphatic Leakage

2021 ◽  
pp. 317-323
Author(s):  
Hashem Bark Awadh Abood ◽  
Atheer Hamad Alatawi ◽  
Abdulaziz Ali ALMohammed ◽  
Mutasim Hassan Alhasani ◽  
Saleh Amir Almutairi ◽  
...  
Keyword(s):  
Lymphatic System ◽  
Interventional Procedure ◽  
Chylous Ascites ◽  
The Body ◽  
Waste Products ◽  
Surgical Closure ◽  
Pharmacological Manipulation ◽  
Lymphatic Fistula ◽  
Underlying Illness ◽  
Flow Through

Lymphatics are found in almost every organ in the body, and they produce a variety of waste products that must be eliminated. lymphatic leakage is a typical occurrence. It can cause immunodeficiency as well as nutritional issues. Furthermore, it has a significant morbidity and death rate, depending on the existence of an underlying illness. Lymphatic leakage can be congenital, traumatic, or cancerous, and occurs when the lymphatic system is disrupted. It might take the following forms: Chylothorax, Lymphatic Fistula, Chylous Ascites. treatment of lymph leaks includes: reduction of lymphatic flow through physiological or pharmacological manipulation; replacement of fluid and electrolytes, as well as interventional procedure and/or direct surgical closure. In this review we’ll be discussing lymphatic system anatomy, its leakage and its management.

Sign in / Sign up

Export Citation Format

Share Document